Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [5292]

AACR 2021: Novel approach to PRMT5 inhibition that selectively targets the PRMT5/MTA complex in MTAP-deleted cancer models

AACR 2021: Novel approach to PRMT5 inhibition that selectively targets the PRMT5/MTA complex in MTAP-deleted...

AACR 2021: Unselected autologous tumour infiltrating lymphocyte therapy shows early promise in patients with metastatic melanoma

AACR 2021: Unselected autologous tumour infiltrating lymphocyte therapy shows early promise in patients with...

$AACR 2021: Bispecific CAR T-cell therapy shows early promise for relapsed or refractory B-cell lymphoma$

AACR 2021: Bispecific CAR T-cell therapy shows early promise for relapsed or refractory B-cell lymphoma

AACR 2021: Resistance to immunotherapy in patients with urothelial bladder cancer is traced to specific sets of immune cells

AACR 2021: Resistance to immunotherapy in patients with urothelial bladder cancer is traced to specific sets of...

AACR 2021: Immune-stimulating drug before surgery shows promise in early-stage pancreatic cancer

AACR 2021: Immune-stimulating drug before surgery shows promise in early-stage pancreatic cancer

Excellent outcomes reported for first targeted therapy for paediatric Hodgkin lymphoma

Excellent outcomes reported for first targeted therapy for paediatric Hodgkin lymphoma

Mutations in overlooked DNA could have profound impact on survival for bowel cancer patients

Mutations in overlooked DNA could have profound impact on survival for bowel cancer patients

'Patchwork' tumours prevalent across multiple cancer types

'Patchwork' tumours prevalent across multiple cancer types

FDA grants regular approval to sacituzumab govitecan for triple-negative breast cancer

FDA grants regular approval to sacituzumab govitecan for triple-negative breast cancer

Positive results for nivolumab-based combinations in unresectable advanced or metastatic oesophageal cancer

Positive results for nivolumab-based combinations in unresectable advanced or metastatic oesophageal cancer

More from ecancer